Pharmaceuticals, Biotechnology and Life Sciences
Preliminary clinical evidence of Lisaftoclax overcoming venetoclax resistance in myeloid malignancies with a 31.8% overall response rate(ORR) in this subgroup…
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Dec. 08, 2025 (GLOBE NEWSWIRE) — HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13)…
SAN FRANCISCO, Dec. 07, 2025 (GLOBE NEWSWIRE) — Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel…
LOS ANGELES, CA, Dec. 07, 2025 (GLOBE NEWSWIRE) — Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or ”IMMX”), a…
– NXC-201 demonstrated a complete response (CR) rate of 75% (15/20) (at s/u IFE(-) level) by independent review committee –…
SLS009 in combination with AZA/VEN achieved a 46% overall response rate across all cohorts, a 58% overall response rate in…
FOR IMMEDIATE RELEASE — ImCheck Reports Durable Responses and Early Overall Survival Signal with ICT01 in First-line AML at ASH…
DALY 2-EU results show zamtocabtagene autoleucel (zamto-cel) demonstrated clinically meaningful superiority over chemoimmunotherapy in patients with relapsed/refractory large B-cell lymphoma…
All three dose groups (50 mg, 100 mg and 200 mg) showed impressive monotherapy efficacy, with VGPR+ (very good partial…
93% overall response and 76% complete response rates with median progression-free survival of 18 months in patients with large B-cell…